Clinical Trials on Scleritis
Total 4343 results
-
Barnes Retina InstituteCompletedNuclear Sclerotic CataractUnited States
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedSubjects With Severe, Refractory Sclerotic Skin ChangesUnited States
-
National Cancer Institute (NCI)CompletedSclerotic Graft Versus Host Disease | Imatinib MesylateUnited States
-
The Eye Center and The Eye Foundation for Research...CompletedScleritis and EpiscleritisSaudi Arabia
-
Chung-Ang University Hosptial, Chung-Ang University...Ministry of Science, ICT and Future PlanningCompletedNecrotizing ScleritisKorea, Republic of
-
Hospices Civils de LyonWithdrawnIdiopathic Refractory Scleritis
-
John KempenCompletedNon-infectious, Non-necrotizing Anterior ScleritisUnited States
-
Medical University of GrazRecruitingMorphea (Circumscribed Scleroderma) | Sclerotic Graft-versus-host Disease (GVHD)Austria
-
National Eye Institute (NEI)Completed
-
National Eye Institute (NEI)The Emmes Company, LLCCompleted
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
Metropolitan Eye Research & Surgery InstituteStanford University; Mallinckrodt; Ocular Imaging Research and Reading Center; Foresight...RecruitingScleritisUnited States
-
National Eye Institute (NEI)Completed
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
BayerCompletedSecondary Progressive Multiple Sclerosis (SPMS) | Relapsing Remitting Multiple Sclerosis (RRMS)Portugal
-
Rebecca SpainCompletedComparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple SclerosisProgressive Multiple Sclerosis | Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); Blood...RecruitingRelapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsActive, not recruitingRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Imperial College LondonGlaxoSmithKline; University College, London; Medical Research Council; Queen Mary... and other collaboratorsCompletedRelapsing-remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
University Hospital, MontpellierCompletedProgressive Multiple Sclerosis | Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | ControlsFrance
-
University of South FloridaGenentech, Inc.Active, not recruitingPathologic Processes | Nervous System Diseases | Immune System Diseases | Multiple Sclerosis | Demyelinating Diseases | Autoimmune Diseases | Relapsing Remitting Multiple Sclerosis | Primary Progressive Multiple SclerosisUnited States
-
Johns Hopkins UniversityCompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkUniversity of Copenhagen; Biogen; Copenhagen University Hospital, Hvidovre; Signifikans...CompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Johns Hopkins UniversityUnited States Department of DefenseCompletedMultiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary ProgressiveUnited States
-
Johns Hopkins UniversityCompletedMultiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary ProgressiveUnited States
-
University of LouisvilleBayer Healthcare Pharmaceuticals, Inc./Bayer Schering PharmaCompletedMultiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Relapsing-remittingUnited States
-
National Eye Institute (NEI)Terminated
-
Assistance Publique - Hôpitaux de ParisCompletedMultiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary ProgressiveFrance
-
University of California, Los AngelesRecruitingPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University College DublinCompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisIreland
-
Innate ImmunotherapeuticsNational Multiple Sclerosis Society; Primorus Clinical TrialsCompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisNew Zealand
-
BiogenWithdrawn
-
Novartis PharmaceuticalsTerminatedRelapse Remitting Multiple SclerosisUnited States, Ukraine, Czechia
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)